Understanding the human metagenome's role in metabolic diseases
Understanding the Role of the Human Metagenome in Obesity, Metabolic Diseases, Chronic Inflammation, Sarcopenia and Sarcopenic Obesity - a Pilot Study
This study is trying to see how the bacteria and substances in our bodies relate to health and conditions like obesity and muscle loss by looking at samples from different people.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 600 (estimated) |
| Ages | 21 Years to 99 Years |
| Sex | All |
| Sponsor | Sengkang General Hospital Academic / other |
| Locations | 1 site (Singapore) |
| Trial ID | NCT06363253 on ClinicalTrials.gov |
What this trial studies
This observational cohort study aims to explore the role of the human metagenome and associated metabolites in health and various metabolic diseases, particularly obesity and sarcopenia. Participants will provide fecal, salivary, urine, serum, and mucosal samples for metagenomic sequencing and metabolite analysis. The study seeks to identify differences in the metagenome and metabolome across different health states, with the potential for future personalized therapeutic applications. A cohort of healthy controls will also be included for comparison.
Who should consider this trial
Good fit: Ideal candidates include individuals who are obese, sarcopenic, or healthy controls without obesity or sarcopenia.
Not a fit: Patients with intestinal stomas or those unable to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to personalized treatment strategies for patients with metabolic disorders.
How similar studies have performed: While the approach of studying the metagenome in relation to metabolic diseases is gaining interest, this specific study's focus on non-bacteriome species and their metabolites is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria (obese cohort): * Obese (BMI\>27.5kg/m2) Inclusion Criteria (sarcopenic cohort): * Sarcopenic patients, defined as 1) low handgrip strength (\<26 for males; \<18kg for females), AND/OR low gait speed (\<0.8m/s) AND low muscle mass (\<7.0kg/m2 for males; \<5.7kg/m2 for females) Inclusion Criteria (control cohort): \- Healthy subjects without sarcopenia, and not obese (BMI\<27.5kg/m2) Exclusion Criteria: * No informed consent * Presence of intestinal stoma, hence inability to collect fecal samples
Where this trial is running
Singapore
- Sengkang General Hospital — Singapore, Singapore (Recruiting)
Study contacts
- Study coordinator: Koy Min Chue
- Email: chue.koy.min@singhealth.com.sg
- Phone: 69305000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.